EBDVD common mistakes
EBDVD · Understand the traps and how to avoid them.
Opening the answer with a disease name ("this is psoriasis") instead of first assigning the visible reaction pattern and then narrowing a differential.
Candidates rehearse prototype images per disease and pattern-match the single most familiar feature; board vignettes deliberately mix features (psoriasiform eczema, lichenoid drug eruption, interface dermatitis of lupus vs lichen planus) so prototype matching collapses under time pressure.
What to do instead
Rehearse a fixed two-step script aloud: name the reaction pattern (spongiotic, psoriasiform, interface/lichenoid, vesiculobullous, granulomatous, vasculitic, panniculitic), list three or four differentials, then eliminate using distribution, chronology, mucosal/nail involvement and systemic symptoms before committing to one diagnosis.
Reciting dermoscopic criteria (pigment network, regression, blue-white veil) and then closing with "benign, reassure" without stating a management action or the threshold that would trigger biopsy.
Dermoscopy is learned as a vocabulary list and a set of algorithms rather than as a decision tool; candidates fear committing to a management plan and default to the benign option, or over-call melanoma on a pink/amelanotic lesion where the algorithm does not apply.
What to do instead
End every dermoscopy answer with an explicit management sentence tied to the worst-case differential (excise, biopsy, photograph and review in X months), use the comparative/ugly-duckling approach when several lesions are present, and restrict the two-step algorithm to clearly pigmented lesions while defaulting to biopsy for amelanotic and pink tumours.
Taking the sexual history as a single question about discharge, and answering a syphilis or gonorrhoea vignette from test names alone without separating treponemal from non-treponemal assays, accounting for the serological window, or mentioning partner notification.
Venereology exposure in training is often brief and outpatient-based, so candidates reduce a sexual history to symptom questions and treat serology as a yes/no result rather than a titre that must be interpreted against time since exposure and treatment history.
What to do instead
Use a structured sexual history (number and gender of partners, practices, barrier use, date of last exposure, prior STI and HIV status, contraception) and a fixed serology algorithm: treponemal EIA/TPPA for screening, RPR/VDRL titre quantified and tracked over time, prozone considered in high-risk or late presentations, and partner notification plus HIV/other STI screening stated in every answer.
Giving an excision margin from memory without first stating the tumour type, Breslow thickness or risk group, and omitting the staging investigation, sentinel-node discussion and surveillance schedule from the plan.
Margins are memorised as an undifferentiated list of numbers rather than as decisions conditional on histology, site and patient factors, and oncology questions are treated as surgical questions rather than as a pathway from diagnosis to follow-up.
What to do instead
Answer in conditional form: state the histological risk determinants first, then the margin (for melanoma in situ 0.5 cm, Breslow up to 1 mm 1 cm, 1-2 mm 1-2 cm, over 2 mm 2 cm, adapted to site), then add the staging step, the sentinel-node threshold, the MDT referral trigger and a named follow-up interval with the reason for it.
Answering a procedural vignette with technique only, leaving out consent, site marking, the anatomical danger zones relevant to that site (temporal branch of the facial nerve, saphenous/sural nerve and distal perforators at the ankle, marginal mandibular nerve) and how the specimen will be oriented for histology.
Surgery is perceived as a manual skill examined separately from communication and safety, so candidates never build a routine that forces these elements into the answer.
What to do instead
Use a spoken pre-operative checklist as the answer template for every surgical stem: indication and expected histology, consent including scar, nerve and recurrence risk, site marking and side verification, anaesthesia and haemostasis, danger-zone anatomy named for that specific site, specimen orientation and suture/closure choice, and post-operative wound-care instructions.
Prescribing an adult-potency topical corticosteroid in an adult quantity to an infant, and answering a genodermatosis vignette with the skin diagnosis only, omitting growth, development and the organ-based surveillance protocol.
Paediatric dosing is taught as a percentage of adult dose rather than as fingertip units per age band and site, and genodermatoses are memorised as morphology plus genetics without the surveillance that actually determines outcome.
What to do instead
Calculate quantity in fingertip units by age and body site, choose the lowest potency that controls the disease and state the intended duration and tapering, then add the surveillance package for the named condition (annual blood pressure, growth and neurodevelopmental review plus ophthalmology in neurofibromatosis type 1; renal and cerebral imaging, epilepsy and lung screening in tuberous sclerosis complex) and mention safeguarding or family screening where relevant.
Reading patch tests only once at 48 hours, scoring a doubtful or weak reaction as negative, or reporting a morphological reaction as allergic without establishing relevance to the patient's exposure.
The technique is learned as a practical skill rather than as an interpretive one, so candidates confuse the reading schedule and the morphology-based scoring with the separate judgement of allergic versus irritant and relevant versus incidental.
What to do instead
State the schedule explicitly (typically day 2 and day 4, with a further late reading for suspected late or corticosteroid reactions), interpret morphology using the standard doubtful/weak/strong/extreme/irritant categories, and always close with relevance: exposure source, occupational or cosmetic product, and the avoidance advice that follows.
Ordering an antinuclear antibody panel as a screening test and diagnosing a connective tissue disease from a low-titre homogeneous result, or failing to review the drug list when a patient presents with a photosensitive or subacute lupus-like eruption.
Antibody tests are treated as diagnostic rather than as probabilistic adjuncts, and drug-induced and paraneoplastic mimics are not held in mind because the classical idiopathic prototypes are over-learned.
What to do instead
Anchor testing to a defined clinical phenotype and state the pre-test probability before naming the test; interpret titres and patterns together with clinical criteria rather than in isolation; and in any suspected lupus or dermatomyositis eruption actively review recent and long-term drugs, screen for malignancy where the phenotype warrants it, and name the classification criteria being applied.
Recommending an ablative laser, high-fluence intense pulsed light or a deep chemical peel in a patient with Fitzpatrick IV-VI skin without discussing post-inflammatory hyperpigmentation risk, test spots, photoprotection and realistic expectations.
Devices are learned by indication rather than by target chromophore and skin phototype, and cosmetic counselling is treated as an afterthought to the procedure choice.
What to do instead
Select the device by target chromophore, depth and the patient's phototype, always include a test spot and an interval before full treatment in higher phototypes, pair the plan with explicit pigmentary-risk counselling and sun protection, and state expected benefit, number of sessions, downtime and the limits of what will not change.
Answering a management question with the treatment the candidate personally favours rather than the guideline-recommended pathway, and omitting the monitoring, teratogenicity and counselling obligations attached to that drug.
Guidelines are read as background rather than as the standard against which the answer is marked, and drug safety monitoring is memorised in isolation from the prescribing decision so it never surfaces in the plan.
What to do instead
Frame every management answer as indication, first-line per current guideline with the guideline named, alternative if first-line fails or is contraindicated, then a safety block covering baseline and on-treatment monitoring, pregnancy prevention and fertility counselling, interaction review and the follow-up interval, finishing with what the patient must be told and how adherence and consent are documented.